In 2024, Philip Morris International's (PMI) website stated they support 'independent' continuing medical education courses on harm reduction for medical and other healthcare professionals. These courses mirrored industry marketing and political strategies by presenting smokeless tobacco products and e-cigarettes as alternatives to smoking, sometimes without mentioning tobacco cessation. The enactment of the US Family Smoking and Tobacco Control Act gave the US Food and Drug Agency jurisdiction over tobacco products and included the industry's 'continuum of risk' frame, and emboldened tobacco companies to make harm reduction claims about these products, which they had previously avoided for fear of triggering restrictive regulation of cigarettes. Opposition from the medical and public health community in the USA and beyond led one large company that partnered with PMI to offer the US courses to withdraw. The Foundation for a Smoke-Free World (renamed Global Action to End Smoking in 2024) created by PMI also funded a non-profit to develop continuing medical education on harm reduction. US accrediting bodies for healthcare education do not have policies against certifying tobacco-sponsored courses, and there needs to be ongoing vigilance against such efforts around the world as well as efforts to secure policies at accrediting organisations to not accredit such industry efforts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/tc-2024-059015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of urban sprawl due to migration on spatiotemporal land use-land cover change: a case study of Bartın in Türkiye.
Sci Rep
January 2025
Department of Forest Engineering, Faculty of Forestry, Kastamonu University, Kastamonu, Türkiye, Turkey.
Rapid urban growth is a subject of worldwide interest due to environmental problems. Population growth, especially migration from rural to urban areas, leads to land use and land cover (LULCC) changes in urban centres. Therefore, LULCC and urban growth analyses are among the studies that will help decision-makers achieve better sustainable management and planning.
View Article and Find Full Text PDFManaging xylazine-involved overdoses in a community harm reduction setting: lessons from Tijuana, Mexico.
Harm Reduct J
January 2025
Asociación Bajacaliforniana de Salud Pública A.C, Tijuana, Baja California, Mexico.
Background: Xylazine is a α2-adrenergic receptor agonist, used for sedation in veterinary contexts. Although it is increasingly found in overdose deaths across North America, the clinical management of xylazine-involved overdoses has not been extensively studied, especially in community-based harm reduction settings. Here we present a clinical series of xylazine-involved overdose and share the clinical approach and lessons learned by a community overdose response team in Tijuana, Mexico amidst the arrival of xylazine.
View Article and Find Full Text PDFProviding an e-cigarette starter kit for smoking cessation and reduction as adjunct to usual care to smokers with a mental health condition: findings from the ESCAPE feasibility study.
BMC Psychiatry
January 2025
Department of Behavioural Science and Health, University College London, London, 1-19 Torrington Place, WC1E 7HB, UK.
Background: Smoking rates in the UK have declined steadily over the past decades, masking considerable inequalities, as little change has been observed among people with a mental health condition. This trial sought to assess the feasibility and acceptability of supplying an electronic cigarette (e-cigarette) starter kit for smoking cessation as an adjunct to usual care for smoking cessation, to smokers with a mental health condition treated in the community, to inform a future effectiveness trial.
Methods: This randomised controlled feasibility trial, conducted March-December 2022, compared the intervention (e-cigarette starter kit with a corresponding information leaflet and demonstration with Very Brief Advice) with a 'usual care' control at 1-month follow-up.
Channelling and taxation in European online gambling markets: evolution and policy implications.
Harm Reduct J
January 2025
Finnish Institute for Health and Welfare, Mannerheimintie 166, 00271, Helsinki, Finland.
Background: Taxation can be used to direct consumption and provision of harmful commodities. Prior research on gambling taxation has nevertheless been inconclusive on whether this can also apply to gambling. In gambling policy, optimal taxation rates have particularly been debated from the perspective of channelling consumption from offshore markets to regulated markets.
View Article and Find Full Text PDFHistorical and political context for Philip Morris International's continuing medical education courses on harm reduction.
Tob Control
January 2025
Retired, University of California San Francisco, San Francisco, California, USA.
In 2024, Philip Morris International's (PMI) website stated they support 'independent' continuing medical education courses on harm reduction for medical and other healthcare professionals. These courses mirrored industry marketing and political strategies by presenting smokeless tobacco products and e-cigarettes as alternatives to smoking, sometimes without mentioning tobacco cessation. The enactment of the US Family Smoking and Tobacco Control Act gave the US Food and Drug Agency jurisdiction over tobacco products and included the industry's 'continuum of risk' frame, and emboldened tobacco companies to make harm reduction claims about these products, which they had previously avoided for fear of triggering restrictive regulation of cigarettes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!